Intuitive Surgical's 2025 earnings were strong, and the future remains bright, with valuation as the only big concern for investors.

Intuitive Surgical receives FDA clearance for the da Vinci 5 robot to be used in cardiac procedures, reports 18% procedure ...

Intuitive Surgical received FDA clearance for its da Vinci 5 system in selected cardiac procedures, including mitral valve repair and cardiac revascularization. The approval enables minimally invasive ...

Intuitive Surgical, Inc. ISRG is expected to grow earnings by the double digits in 2026 and 2027. This Zacks Rank #1 (Strong Buy) is still the industry leader in robotic-assisted surgery. Intuitive ...

The FDA 510(k) clearances for cardiac procedures cover Intuitive's latest-generation da Vinci 5 (DV5) using non-Force ...

With nine new procedures cleared for the da Vinci 5 robot, Intuitive’s strategy includes working with a limited number of U.S ...

Intuitive Surgical capped off the recovery in its shares with a strong Q4 2025 earnings release, lending support to the stock ...

Intuitive Surgical has received FDA clearance for cardiac procedures using the da Vinci 5 surgical robot, according to a Jan. 26 report from Mass Device. The new cardiac clearances cover mitral valve ...

The design of da Vinci 5 can support minimally invasive cardiac procedures by enabling surgeons to operate through small incisions without opening the breastbone. The system offers: 10,000x computing ...

The robotics giant revealed on an earnings call that it won FDA clearance for several cardiac procedures and is also ramping up its presence in ambulatory surgery centers.

Intuitive Surgical (NASDAQ: ISRG) will report its Q2 2024 results on Thursday, July 18. We expect the company’s revenues to come in at $2 billion and adjusted earnings to be $1.55 per share, broadly ...

Intuitive's da Vinci SP surgical system receives FDA clearance for transanal local resection, enhancing minimally invasive colorectal surgery options. Intuitive, a leader in robotic-assisted surgery, ...